The U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks Therapeutics, Inc.’s MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company […]

The production of energy that powers cells and facilitates their operation depends on mitochondria. On the other hand, disorders like type 2 diabetes are linked to mitochondrial abnormalities. Individuals with this condition are unable to use the insulin their pancreas produces to maintain normal blood sugar levels or create enough […]

The codon chart is an important tool in the fields of molecular biology and genetics, allowing the translation of the genetic code into specific amino acids, creating the basis for protein synthesis in all life forms. The interpretation of the codon chart implies comprehension of the structure of genetic material […]

Skip to content